NewAmsterdam Pharma Company N.V. Operating Expenses
NewAmsterdam Pharma Company N.V. (NAMS) reported Operating Expenses of $68.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. operating expenses for the quarter ending 2026-06-30 was $68.56M, a 25.16% increase year-over-year.
- NewAmsterdam Pharma Company N.V. operating expenses for the quarter ending 2026-03-31 was $61.46M, a 14.52% decline year-over-year.
- NewAmsterdam Pharma Company N.V. operating expenses for the quarter ending 2025-12-31 was $66.01M, a 17.88% increase year-over-year.
- NewAmsterdam Pharma Company N.V. operating expenses for the quarter ending 2025-09-30 was $55.49M, a 2.54% increase year-over-year.
- NewAmsterdam Pharma Company N.V. operating expenses for fiscal 2025 was $248.19M, a 11.87% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. operating expenses for fiscal 2024 was $221.85M, a 12.58% increase from fiscal 2023.
- NewAmsterdam Pharma Company N.V. operating expenses for fiscal 2023 was $197.06M, a 85.46% increase from fiscal 2022.
- NewAmsterdam Pharma Company N.V. operating expenses for fiscal 2022 was $106.25M, a 203.77% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $68.56M 10-Q · filed 2026-08-05 | $130.03M 10-Q · filed 2026-08-05 | $196.04M derived: sum of 3 quarters · filed 2026-08-05 | $251.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $61.46M 10-Q · filed 2026-05-07 | $127.47M derived: sum of 2 quarters · filed 2026-05-07 | $182.96M derived: sum of 3 quarters · filed 2026-05-07 | $237.74M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $66.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $121.50M derived: sum of 2 quarters · filed 2026-02-18 | $176.28M derived: sum of 3 quarters · filed 2026-08-05 | $248.19M 10-K · filed 2026-02-18 |
| 2025-09-30 | $55.49M 10-Q · filed 2025-11-05 | $110.27M derived: sum of 2 quarters · filed 2026-08-05 | $182.17M 10-Q · filed 2025-11-05 | $238.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $54.78M 10-Q · filed 2026-08-05 | $126.68M 10-Q · filed 2026-08-05 | $182.68M derived: sum of 3 quarters · filed 2026-08-05 | $236.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $71.90M 10-Q · filed 2026-05-07 | $127.90M derived: sum of 2 quarters · filed 2026-05-07 | $182.02M derived: sum of 3 quarters · filed 2026-05-07 | $236.87M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $56.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $110.11M derived: sum of 2 quarters · filed 2026-02-18 | $164.97M derived: sum of 3 quarters · filed 2026-02-18 | $221.85M 10-K · filed 2026-02-18 |
| 2024-09-30 | $54.11M 10-Q · filed 2025-11-05 | $108.97M derived: sum of 2 quarters · filed 2025-11-05 | $165.85M 10-Q · filed 2025-11-05 | $217.73M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-30 | $54.85M 10-Q · filed 2025-08-06 | $111.74M 10-Q · filed 2025-08-06 | $163.61M derived: sum of 3 quarters · filed 2026-02-18 | $216.11M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-31 | $56.88M 10-Q · filed 2025-05-08 | $108.76M derived: sum of 2 quarters · filed 2026-02-18 | $161.26M derived: sum of 3 quarters · filed 2026-02-18 | $205.46M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-31 | $51.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $104.38M derived: sum of 2 quarters · filed 2026-02-18 | $148.57M derived: sum of 3 quarters · filed 2026-02-18 | $197.06M 10-K · filed 2026-02-18 |
| 2023-09-30 | $52.50M 10-Q · filed 2024-11-06 | $96.70M derived: sum of 2 quarters · filed 2024-11-06 | $145.18M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $44.20M 10-Q · filed 2024-08-07 | $92.68M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $48.48M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $106.25M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $34.98M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |